Introduction
Ovarian cancer remains a significant challenge in gynecologic oncology, often referred to as a "silent killer" due to its asymptomatic progression. Approximately 70% of patients are diagnosed at an advanced stage, leading to high recurrence rates and a low five-year survival rate. The standard therapeutic approach for advanced cases typically involves Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) to achieve maximal cytoreduction.
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has established efficacy as a maintenance therapy post-surgery. However, its integration into the NACT phase remains controversial. This study investigates whether adding bevacizumab to preoperative chemotherapy improves surgical outcomes without compromising safety through increased perioperative complications.
Methodology
This systematic evaluation and meta-analysis were conducted following the INPLASY protocol. The researchers performed a comprehensive literature search across PubMed, Embase, and the Cochrane Library to identify relevant clinical data.
Inclusion Criteria and Data Extraction
The analysis focused on randomized controlled trials (RCTs) and cohort studies published in English. Eligible studies reported on:
- Progression-free survival (PFS)
- Rates of complete or satisfactory tumor resection (R0/R1)
- Adverse events and surgical complications
Statistical Approach
Data were analyzed using Stata 15.0, employing both fixed-effects and random-effects models. Results were expressed as Relative Risk (RR) for binary outcomes and Hazard Ratios (HR) for survival data. Publication bias was assessed via funnel plots and Egger’s test to ensure the robustness of the findings.
Results and Analysis
The meta-analysis synthesized data from five eligible studies involving a total of 371 patients. The experimental group (TCB) consisted of 160 patients receiving Paclitaxel, Carboplatin, and Bevacizumab, while the control group (TC) included 211 patients receiving standard Paclitaxel and Carboplatin.
Efficacy Outcomes
The addition of bevacizumab did not significantly improve surgical success rates. The pooled RR for satisfactory tumor reduction (R0+R1) was 1.124 (95% CI: 0.947–1.335, p=0.182). Furthermore, there was no evidence that preemptive bevacizumab prolonged progression-free survival (PFS) compared to standard NACT alone.
Safety and Tolerability
Contrary to clinical concerns regarding anti-angiogenic agents and wound healing, the study found the TCB regimen to be safe and feasible:
- Perioperative Complications: The pooled RR for surgical complications (e.g., bleeding, infection, impaired healing) was 0.955 (95% CI: 0.672–1.359, p=0.799), indicating no increased risk.
- General Toxicity: The pooled RR for chemotherapy-related adverse events (such as anemia or fever) was 0.88 (95% CI: 0.713–1.088, p=0.238), suggesting no significant increase in systemic toxicity.
Discussion
The findings dispel the "safety myth" that bevacizumab significantly increases surgical risks when administered in the neoadjuvant setting. However, the lack of a corresponding "efficacy boost" suggests a gap between theoretical anti-angiogenic benefits and clinical outcomes in the preoperative window.
The stagnation in survival and resection rates implies that the timing of bevacizumab administration is critical. While effective in maintenance settings, the NACT phase may not be the optimal window for its introduction, or its effects may be masked by the high efficacy of standard platinum-based chemotherapy in treatment-naive patients.
Limitations and Future Directions
Several factors limit the generalizability of these findings:
- Sample Size: The inclusion of only 371 patients across five studies may limit the statistical power to detect minor clinical benefits.
- Study Heterogeneity: Mixing RCTs with cohort studies introduces potential selection and reporting biases.
- Language Bias: The exclusion of non-English studies may have omitted relevant regional data.
Conclusion
While the addition of bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer is safe and feasible, it does not appear to significantly improve tumor reduction or progression-free survival. Clinicians should carefully weigh the costs and potential lack of incremental benefit when considering bevacizumab in the preemptive phase. Future research should focus on larger, multi-center RCTs to identify specific patient subgroups that might derive benefit from this combination.
Summary updated